The Vanguard Group 13D and 13G filings for Agios Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-12 11:21 am Purchase | 2024-01-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | The Vanguard Group | 5,599,917 10.020% | 72,479 (+1.31%) | Filing |
| 2024-02-12 10:50 am Purchase | 2023-12-29 | 13G | Agios Pharmaceuticals, Inc. AGIO | The Vanguard Group | 5,527,438 9.890% | 192,362 (+3.61%) | Filing |
| 2023-02-09 10:54 am Purchase | 2022-12-30 | 13G | Agios Pharmaceuticals, Inc. AGIO | The Vanguard Group | 5,335,076 9.710% | 266,486 (+5.26%) | Filing |
| 2022-02-09 3:16 pm Sale | 2021-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | The Vanguard Group | 5,068,590 9.330% | -415,984 (-7.58%) | Filing |
| 2021-12-09 1:54 pm Sale | 2021-11-30 | 13G | Agios Pharmaceuticals, Inc. AGIO | The Vanguard Group | 5,484,574 10.100% | -141,139 (-2.51%) | Filing |
| 2021-02-10 10:30 am Purchase | 2020-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | The Vanguard Group | 5,625,713 8.120% | 18,858 (+0.34%) | Filing |